Nadine El Asmar, MD
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1649568080
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,823 of the $2,113 with a category attached, or 86.3%. It is spread thinly across 18 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $729 and has fallen 77.3% since, to $165 in 2025.
Across 51 payments — averaging $41.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$497
- Sanofi-aventis U.S. LLC$462
- AstraZeneca$254
- Amgen$175
- Lilly USA, LLC$137
- Dexcom, Inc.$127
- plus $460 from 12 others
Across 15 payments — averaging $1185.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$18K
What the payments were for
- Food & beverage$1,82386%
- Education$29014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $497 |
| Sanofi-aventis U.S. LLC | 7 | $462 |
| AstraZeneca | 2 | $254 |
| Amgen(2 entities) | 3 | $175 |
| Lilly USA, LLC | 6 | $137 |
| Dexcom, Inc. | 3 | $127 |
| Pfizer | 1 | $115 |
| Recordati_rare_diseases_inc. | 3 | $64 |
| Insulet Corporation | 1 | $50 |
| Abbott | 2 | $48 |
| Astellas Pharma US Inc | 2 | $37 |
| BETA Bionics, Inc. | 1 | $35 |
| Medtronic | 1 | $28 |
| Boehringer Ingelheim | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Halozyme Inc | 1 | $16 |
| AbbVie | 1 | $15 |
| Dynavax Technologies Corporation | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,113 in reported general payments places this provider in the 55th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 88 | $124,437 |
| OzempicSemaglutide | 84 | $112,953 |
| JardianceEmpagliflozin | 92 | $94,352 |
| RybelsusSemaglutide | 13 | $33,810 |
| MounjaroTirzepatide | 26 | $31,869 |
| JanuviaSitagliptin Phosphate | 29 | $27,352 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $20,498 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $19,947 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 18 | $17,156 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $7,443 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 53 | $6,253 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $6,251 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $6,191 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,975 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $5,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $137 | $156,307114 claims |
| Novo NordiskOzempic, Rybelsus | $497 | $146,76397 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $25 | $100,543103 claims |
| AbbVieSynthroid | $15 | $1,90917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
Other endocrinology, diabetes & metabolism in Washington
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
- Mark SklarWashington$14K
- Sabyasachi SenWashington$12K
- Rui LuWashington$12K
- Qudsia HussainWashington$9K
- Jerold ShareWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.